Real-World 52-Week Effectiveness of Deucravacitinib in Psoriasis: A Stratified Analysis by Age and Body Mass Index

Real-World 52-Week Effectiveness Study of Deucravacitinib in Psoriasis Background Introduction Psoriasis is a chronic inflammatory skin disease with a global prevalence of approximately 1% to 3%. This condition not only affects patients’ quality of life (QoL) but is also often accompanied by comorbidities such as cardiovascular diseases, diabetes, ...

Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma

Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma

Study on Real-world Outcomes of First-line Immune Checkpoint Inhibitor Therapy in Metastatic Melanoma Predicted by Tumor Mutational Burden The treatment of metastatic melanoma has significantly benefited from immune checkpoint inhibitors (ICIs) in recent years. However, despite the remarkable improvement in survival rates among melanoma patients, t...

Efficacy-Effectiveness Analysis on Survival in a Population-Based Real-World Study of BRAF-Mutated Metastatic Colorectal Cancer Patients Treated with Encorafenib-Cetuximab

Efficacy-Effectiveness Analysis of Encorafenib-Cetuximab Treatment in Patients with Oncogene-Mutated Metastatic Colorectal Cancer: A Cohort Study Research Background With the advancement of personalized medicine, targeted therapy has become an important means to treat various cancers. In metastatic colorectal cancer (mCRC), the combination of encor...